Galapagos NV
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
10 jun 2015 - 07:30
Statutaire naam
Galapagos NV
Titel
Galapagos DARWIN 1 and 2 studies have completed 24 weeks of treatment
Bericht
Last of 886 enrolled rheumatoid arthritis (RA) patients have completed the 24 week visit
Topline results from final analyses expected to be released in July and August 2015
Mechelen, Belgium; 10 June 2015 - Galapagos NV (Euronext & NASDAQ: GLPG), a clinical stage biotechnology company focused on developing novel mode of action medicines, announces that the last RA patients in its DARWIN 1 and 2 dose finding studies with filgotinib have completed their final visit. This triggers the clinical research organization's process of last 24 week data collection from both studies, to be followed by final database lock and analysis. Galapagos expects to announce topline results in late July (DARWIN 1) and in August (DARWIN 2) 2015.
Datum laatste update: 07 februari 2025